Literature DB >> 25610748

Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents.

Jonathan M Weiss1, Robert H Wiltout1.   

Abstract

Therapeutic targeting of the CD40 pathway may be efficacious for cancer treatment. Accumulating evidence suggests synergistic and unique antitumor responses may be achieved using CD40-based therapies in combination with other immunomodulators or targeted agents.

Entities:  

Keywords:  biomarkers; immunostimulation; immunotherapy; inflammation; targets; therapeutic antibodies

Year:  2014        PMID： 25610748      PMCID： PMC4292511          DOI： 10.4161/21624011.2014.954483

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo.

Authors:  M Melter; M E Reinders; M Sho; S Pal; C Geehan; M D Denton; D Mukhopadhyay; D M Briscoe
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer.

Authors:  David J DiLillo; Takashi Matsushita; Thomas F Tedder
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

3.  CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.

Authors:  A G Eliopoulos; C Davies; P G Knox; N J Gallagher; S C Afford; D H Adams; L S Young
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

4.  Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.

Authors:  Lynnette Shorts; Jonathan M Weiss; Jong-Keuk Lee; Lisbeth A Welniak; Jeffrey Subleski; Timothy Back; William J Murphy; Robert H Wiltrout
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

5.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Authors:  Qun Jiang; Jonathan M Weiss; Timothy Back; Tim Chan; John R Ortaldo; Sylvie Guichard; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

6.  CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Authors:  Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

7.  Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Authors:  Jonathan M Weiss; Jeff J Subleski; Tim Back; Xin Chen; Stephanie K Watkins; Hideo Yagita; Thomas J Sayers; William J Murphy; Robert H Wiltrout
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

8.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Authors:  Jonathan M Weiss; Lisa A Ridnour; Tim Back; S Perwez Hussain; Peijun He; Anna E Maciag; Larry K Keefer; William J Murphy; Curtis C Harris; David A Wink; Robert H Wiltrout
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

9.  Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Authors:  Jonathan M Weiss; Timothy C Back; Anthony J Scarzello; Jeff J Subleski; Veronica L Hall; Jimmy K Stauffer; Xin Chen; Dejan Micic; Kory Alderson; William J Murphy; Robert H Wiltrout
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

10.  Agonistic CD40 antibodies and cancer therapy.

Authors:  Robert H Vonderheide; Martin J Glennie
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531
  10 in total
  1 in total

1.  Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.

Authors:  Susanne M Rittig; Martina S Lutz; Kim L Clar; Yanjun Zhou; Korbinian N Kropp; André Koch; Andreas D Hartkopf; Martina Hinterleitner; Lars Zender; Helmut R Salih; Stefanie Maurer; Clemens Hinterleitner
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.